Vensana—Is Medtech Investing on the Rebound?

article image

After years that saw investors fleeing medical devices, a host of new funds and new entrants are breathing life into medtech start-ups. A case in point: Vensana Capital, a $225 million fund recently launched by industry veterans Kirk Nielsen and Justin Klein.

Just a few years ago, the question, “Why would anyone want to start anew fund in medtech?” would have been deemed rhetorical, with a clear implication that no one would.Indeed, not only were few VCs coming new into the space, many established medtech investors were scaling back or leaving altogether.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: